Safety and efficiency of perilesional sclerotherapy in leg ulcer patients with postthrombotic syndrome and/or oral anticoagulation with phenprocoumon;Sicherheit und effektivität der periulzerösen schaumsklerosierung bei patienten mit postthrombotischem syndrom und/oder oraler antikoagulation mit phenprocoumon

JDDG - Journal of the German Society of Dermatology

Volumn 4, Issue 9, 2006, Pages 734-738

  Stücker, Markus ^a   Reich, Stefanie ^a   Hermes, Nico ^a   Altmeyer, Peter ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Hypercoagulability; Postthrombotic syndrome; Sclerotherapy; Varicosis; Venous leg ulcer

Indexed keywords

PHENPROCOUMON; POLIDOCANOL;

ANTICOAGULATION; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HUMAN; INJECTION SITE EROSION; INJECTION SITE PHLEBITIS; LEG ULCER; POSTTHROMBOSIS SYNDROME; SAMPLE SIZE; SAPHENOUS VEIN; SCLEROTHERAPY; THERAPY EFFECT; TREATMENT OUTCOME; ULCER HEALING; WOUND HEALING;

ADMINISTRATION, ORAL; ANTICOAGULANTS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LEG ULCER; MALE; MIDDLE AGED; PHENPROCOUMON; POSTPHLEBITIC SYNDROME; RISK ASSESSMENT; SCLEROTHERAPY; SYNDROME; TREATMENT OUTCOME;

EID: 33748478094     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2006.06085.x     Document Type: Article

References (13)

1. Barwell JR, Davies CE, Deacon J, Harvey K, Minor J, Sassano A, Taylor M, Usher J, Wakely C, Earnshaw JJ, Heather BP, Mitchell DC, Whyman MR, Poskitt KR. Comparison of surgery and compression with compression alone in chronic venous ulceration (ESCHAR study): randomized controlled trial. Lancet 2004; 5; 363: 1854-1859.
2. Iafrati MD, Pare GJ, O'Donnell TF, Estes J. Is the nihilistic approach to surgical reduction of superficial and perforator vein incompetence for venous ulcer justified? J Vasc Surg 2002; 36:1167-1174.
3. Kalra M, Gloviczki P. Subfascial endoscopic perforator vein surgery: who benefits? Semin Vasc Surg 2002; 15:39-49.
4. Queral LA, Criado FJ, Lilly MP, Rudolphi D. The role of sclerotherapy as an adjunct to Unna's boot for treating venous ulcers: a prospective study. J Vasc Surg. 1990; 11:572-575.
5. Hübner K. Beschleunigung der Abheilung des chronischen, therapieresistenten Ulcus cruris venosum durch die Sklerotherapie periulzeröser Varizen. Vasomed 2002; 13:191-195.
6. Tessari L, Cavezzi A, Frullini A: Preliminary experience with a new sclerosing foam in the treatment of varicose veins. Dermatol Surg 2001; 27:58-60.
7. Hamel-Desnos C, Desnos P, Wollmann JC, Ouvry P, Mako S, Allaert FA. Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatol Surg 2003; 29:1170-1175.
8. Rabe E, Pannier-Fischer F, Gerlach H, Breu FX, Guggenbichler S, Zabel M; Guidelines for sclerotherapy of varicose veins (ICD 10: I83.0, I83.1, I83.2, and I83.9). Dermatol Surg 2004; 30:687-693.
9. Gaber Y, Siemens HJ, Schmeller W. Resistance to activated protein C due to factor V Leiden mutation: high prevalence in patients with post-thrombotic leg ulcers. Br J Dermatol 2001; 144: 546-548.
10. Kahn SR, Ginsberg JS. The postthrombotic syndrome: current knowledge, controversies, and directions for future research. Blood Rev 2002; 16:155-165.
11. Kalra M, Gloviczki P, Noel AA, Rooke TW, Lewis BD, Jenkins GD, Canton LG, Panneton JM. Subfascial endoscopic perforator vein surgery in patients with post-thrombotic venous insufficiency - is it justified? Vasc Endovascular Surg 2002; 36:41-50.
12. Gloviczki P, Bergan JJ, Menawat SS, Hobson RW 2nd, Kistner RL, Lawrence PF, Lumsden A, O'Donnell TF, DePalma RG, Murray J, Pigott JP, Schanzer H, Ascer E, Kalman P, Calligaro KD, Ballard JL, Cambria RA, Rhee RY, Rubin BG, Ilstrup DM, Harmsen WS, Canton LG. Safety, feasibility, and early efficacy of subfascial endoscopic perforator surgery: a preliminary report from the North American registry. J Vasc Surg 1997; 25: 94-105.
13. Feied CF. Deep Vein Thrombosis: The risks of sclerotherapy in hypercoagulable states. Sem Dermatol 1993; 12:135-149.